a Glutamate contributes to the reinforcing and stimulant effects of methamphetamine, yet its potential role in the interoceptive stimulus properties of methamphetamine is unknown. In this study, adult male Sprague -Dawley rats were trained to discriminate methamphetamine [1.0 mg/kg, intraperitoneally] from saline in a standard operant discrimination task. The effects of methamphetamine (0.1-1.0 mg/kg, intraperitoneally); N-methyl-D-aspartate (NMDA) receptor channel blockers, MK-801 (0.03-0.3 mg/kg, intraperitoneally) and ketamine (1.0-10.0 mg/kg, intraperitoneally); polyamine site NMDA receptor antagonist, ifenprodil (1-10 mg/kg); a-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptor antagonist, 6-cyano-7-nitroquinoxaline-2,3-dione (1-10 mg/kg, intraperitoneally); and metabotropic 5 glutamate receptor antagonist, 6-methyl-2-(phenylethynyl)pyridine (1-10 mg/kg), given alone were determined in substitution tests. The effects of MK-801 (0.03 and 0.1 mg/kg), ketamine (1.0 and 3.0 mg/kg), ifenprodil (5.6 mg/kg), 6-cyano-7-nitroquinoxaline-2,3-dione (5.6 mg/kg), and 6-methyl-2-(phenylethynyl)pyridine (5.6 mg/kg) were also tested in combination with methamphetamine to assess for alterations in the methamphetamine cue. In substitution tests, none of the test drugs generalized to the methamphetamine cue. However, ketamine and ifenprodil produced significant leftward shifts in the methamphetamine dose-response curve. In addition, the potention by MK-801 nearly attained significance. These results suggest that blockade of the NMDA receptor augments the interoceptive stimulus properties of methamphetamine. Behavioural Pharmacology 22:516-524
Introduction
Methamphetamine abuse is a worldwide public health concern (Watanabe-Galloway et al., 2009; Gonzales et al., 2010) . A major impediment toward reducing the adverse impact of methamphetamine abuse has been the lack of an effective treatment medication (Dwoskin and Crooks 2002; Rothman et al., 2005; Newton et al. 2006) . Although much progress has been made in recent years (Vocci and Appel, 2007; Rothman et al., 2008; Carroll et al., 2009; Horton et al., 2011) , additional research into the underlying mechanisms of methamphetamine abuse will likely be an important aid to further promote medication development efforts.
Preclinical animal models, such as the drug discrimination procedure, are useful tools for identifying receptor mechanisms of drug action in vivo. Studies, using this procedure, to investigate the pharmacology of methamphetamine have identified that the monoamines, dopamine (Munzar and Goldberg, 2000; Czoty et al., 2004a Czoty et al., , 2004b Bergman 2008) , norepinephrine (Munzar and Goldberg, 1999; Czoty et al., 2004b) , and serotonin (Munzar et al., 1999 (Munzar et al., , 2002 Czoty et al., 2004b) , play important roles in the methamphetamine cue. Other studies have revealed that acetylcholine (Gatch et al., 2008; Desai and Bergman, 2010) , adenosine (Munzar et al., 2002; Justinova et al., 2003) , histamine (Munzar et al., 1998; Mori et al., 2002) , and g-amino-butyric acid (Gasior et al., 2004; Gatch et al., 2005) neurotransmitter systems are also involved. These results illustrate the complex nature of the neurochemical events that mediate transduction of methamphetamine's interoceptive effects.
Despite this previous work, the specific involvement of glutamate in methamphetamine discrimination has not been addressed. Glutamate is the predominant excitatory neurotransmitter in mammalian brain, and exerts effects by actions at several distinct receptor subtypes. These include the ligand-gated N-methyl-D-aspartate (NMDA) and a-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) receptor channels, and a variety of G protein-coupled metabotropic glutamate receptor (mGluR 1 -8 ) subtypes. Previous behavioral studies using animal models of drug abuse have identified roles for several glutamate receptor subtypes. For instance, NMDA receptor antagonists reduce methamphetamine-induced hyperactivity (Witkin, 1993) and attenuate methamphetamine self-administration (Glick et al., 2001; Allen et al., 2005; Osborne and Olive, 2008; Gass et al., 2009) . The NMDA antagonist, dextromethorphan, and the metabotropic 5 glutamate receptor (mGluR5) antagonist, 6-methyl-2-(phenylethynyl)pyridine (MPEP), also reduce cocaine self-administration and hyperactivity (Pulvirenti et al., 1997; Herzig and Schmidt, 2004; Paterson and Markou, 2005) . In drug discrimination studies using rats trained to discriminate d-amphetamine or cocaine, the NMDA receptor antagonists, MK-801 and phencyclidine, elicit partial substitution when tested alone and enhance the effects of the training drugs when administered in combination (Kantak et al., 1998; Gaiardi et al., 2001) . Conversely, the glycine site NMDA partial agonist, D-cycloserine, attenuates the effects of d-amphetamine (Gaiardi et al., 2001) . There are two published investigations of the effects of drugs that act preferentially on glutamate using the methamphetamine discrimination procedure (Hart et al., 2002; Gatch and Pratt, 2006) . In the first study, Hart et al. (2002) trained six human participants to discriminate methamphetamine (10 mg) from placebo using a standard two-choice procedure. Next, the effects of methamphetamine (5-20 mg) and the low-affinity noncompetitive NMDA antagonist, memantine (40 mg), given alone or in combination, were then assessed under a threechoice procedure where a 'novel' choice option was available. Although memantine alone did not substitute for methamphetamine, co-administration with methamphetamine resulted in increased 'novel' choice responding, suggesting that the cue produced by the memantine/ methamphetamine combination was distinct from the effects of placebo or methamphetamine alone. In the second study, Gatch and Pratt (2006) examined the effects of NMDA and MK-801 in rats trained to discriminate 1.0 mg/kg of methamphetamine from saline. Results indicated that NMDA (30 mg/kg) did not alter the effects of methamphetamine; however, MK-801 (0.1 mg/kg) produced a two-fold leftward shift in the methamphetamine (0.1-1.0 mg/kg) dose-response curve, suggesting that blockade of NMDA receptors can augment the methamphetamine cue. Thus, evidence obtained in both rodents and humans indicates that NMDA receptor blockade alters the subjective properties of methamphetamine. On the basis of these findings, further testing of ligands that act on NMDA and other receptor subtypes in methamphetamine discrimination is warranted, especially given that these compounds may have some utility as treatments for stimulant abuse (Kalivas, 2007; Markou, 2007) .
The purpose of this study was to examine the potential roles of ionotropic (i.e. NMDA and AMPA) and mGluR5-subtypes in methamphetamine discrimination in rats. The noncompetitive channel blockers, MK-801 and ketamine, and the NR2B subunit polyamine site antagonist, ifenprodil, were tested. Although MK-801 and ketamine have similar mechanisms of action, MK-801 has a greater affinity for NMDA receptors than ketamine (Wong et al., 1986) . The role of the NMDA polyamine recognition site was tested with ifenprodil, which does not block the ion-pore channel (Carter et al., 1989) . The role of AMPA receptors was investigated with the quinoxalinedione derivative, 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), which has a K i value of 300 nmol/l at the AMPA receptor and sevenfold greater selectivity for AMPA than kainate receptors (Shimizu-Sasamata et al., 1996) . The potential role of mGluR5 was examined with the selective antagonist, MPEP (Gasparini et al., 1999) . Each drug was tested alone and in combination with methamphetamine.
Methods

Subjects
Adult male Sprague -Dawley rats (n = 6) were obtained from Harlan Inc. (Indianapolis, Indiana, USA) and housed individually in standard plastic cages in a temperaturecontrolled and humidity-controlled facility set to a 14 : 10 h light/dark cycle (lights on at 06 : 00 h). Rats were handled and acclimated to the colony for 1 week before the start of the experiment, which was conducted during the light phase. Rats were maintained at 85% of their free-feed weights, but had continuous access to water. Experimental protocols were in accordance with the 1996 NIH Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee at the University of Kentucky.
Apparatus
Experiments were conducted in operant conditioning chambers (ENV-008, Med Associates, St Albans, Vermont, USA). Each chamber was housed in a sound-attenuating wooden enclosure (ENV-018 mol/l, Med Associates) and connected to a personal computer through an interface (SG-502, Med Associates). A 5 Â 4.2 cm opening that allowed access to a recessed food tray was located on the response panel of the operant conditioning chamber. Two retractable metal response levers were mounted next to the food tray (one on each side), 7.3 cm above a metal-grid floor. A 28 V, 3-cm-diameter white cue light was centered 6 cm above each response lever.
Procedure
Training phase
Rats were trained initially to lever press for food reinforcement (45 mg Precision Pellets, Bio-Serv, Frenchtown, New Jersey, USA) under a fixed ratio (FR) 1 schedule during a single 60-min training session. The FR requirement for reinforcement was subsequently increased to a terminal FR10 over the next 12 daily sessions, which were of 15 min duration. To enhance discrimination acquisition, only one lever (the salineappropriate lever; counterbalanced across rats) was presented during these sessions. The cue lights were illuminated when the lever was presented to signal the start of each session, and turned off once the lever retracted at the end of the session. After two sessions with the FR10 schedule, the methamphetamine discrimination training phase began. Here, rats received a single injection of either methamphetamine (1.0 mg/kg, intraperitoneally) or saline 15 min before each session. Next, rats were placed in the operant conditioning chamber for daily sessions of 15 min. When methamphetamine was administered, only the lever designated as the methamphetamine-appropriate lever was presented. When saline was administered, only the saline-appropriate lever was presented. The left lever was designated as the methamphetamine-appropriate lever and the right lever was designated as the saline-appropriate lever for half of the rats, whereas lever designations were reversed for the other rats. Methamphetamine and saline were administered according to a double-alternation sequence (i.e. MMSSMMSS or SSMMSSMM) for eight consecutive sessions. From that point on, and for the remainder of the experiment, both levers were presented at each session. Responses on the injection-appropriate lever was reinforced according to the FR10 schedule, and responses on the incorrect lever were recorded but had no programmed consequence. Training continued until the following criteria were met on seven of eight consecutive sessions: (a) no more than 13 total responses were emitted before earning the first reinforcer; and (b) 85% or more of the total session responses occurred on the injectionappropriate lever.
Substitution and interaction tests
Once training criteria were met, test sessions were interspersed between methamphetamine and saline training sessions. Test sessions were similar to training sessions, with the exceptions that (a) they were 3 min in duration, and (b) the completion of 10 responses on either lever was reinforced with food-pellet delivery. Substitution tests were conducted to establish the doseresponse curves for methamphetamine (0.1-1.0 mg/kg, intraperitoneally), MK-801 (0.03-0.3 mg/kg, intraperitoneally), ketamine (1-10 mg/kg, intraperitoneally), ifenprodil (1-10 mg/kg, intraperitoneally), CNQX (1-10 mg/kg, intraperitoneally), and MPEP (1-10 mg/kg, intraperitoneally). Methamphetamine was tested before any of the other drugs, followed by tests with MK-801 and ketamine (counterbalanced order). Tests with ifenprodil, CNQX, and MPEP were then conducted in a random order across rats, although each dose of a particular drug was administered before initiating tests with another drug. Once substitution tests were completed, a second methamphetamine dose-response curve was determined after pretreatment with saline. Then, interaction tests were initiated in which the methamphetamine doseresponse curve (0.1-1.0 mg/kg) was redetermined after pretreatment with saline, MK-801 (0.03 and 0.1 mg/kg), ketamine (1 and 3 mg/kg), ifenprodil (5.6 mg/kg), CNQX (5.6 mg/kg), and MPEP (5.6 mg/kg). Methamphetamine doses were given in a random order for each pretreatment drug. In substitution tests, all drugs were administered 15 min before the session. In interaction tests, all pretreatment drugs were given 15 min before methamphetamine, which was administered 15 min before the session (i.e. pretreatments were given 30 min before the session). At least two 15-min training sessions (one with 1.0 mg/kg of methamphetamine and one with saline) intervened each test session to ensure baseline stability.
Any rat that did not meet the criteria described above for acquisition was not given a dose of any test drug until stable performance re-emerged.
Two dependent measures were collected during each test session: (a) percentage of total responses occurring on the methamphetamine-appropriate lever (calculated as the number of responses on the methamphetamineappropriate lever divided by the total number of responses on each lever); and (b) rate of responding in seconds (calculated as the total number of responses on each lever divided by 180). Although lever selection data from any rats that failed to complete at least 10 responses were excluded from the statistical analyses, data from all rats were included in analyses of response rates.
Drugs
(+)-Methamphetamine HCl, (±)-ketamine HCl, (+)-MK-801 hydrogen maleate, and CNQX disodium salt were obtained from Sigma (St Louis, Missouri, USA). MPEP HCl and ifenprodil hemitartrate were obtained from Tocris Bioscience (Ellisville, Missouri, USA). All drugs were prepared in 0.9% NaCl (saline) with the exception of ifenprodil, which was prepared in distilled water. All drugs were administered intraperitoneally in a volume of 1 ml/kg. Doses indicate the salt weights.
Statistics Dose-response curves were analyzed by one-way or two-way repeated-measures analysis of variance (ANOVA). Lever selection data were subjected to arcsine transformations before ANOVA to increase homogeneity of variance (Winer, 1971) . Response rate data were calculated as the number of responses per second, which were then converted to percentage saline control data. Post-hoc comparisons were conducted in cases where ANOVA returned significant main effects or interactions. Statistical significance was declared at P value less than or equal to 0.05.
Results
Training phase
Rats learned to discriminate methamphetamine from saline in an average of 47.6 (± 23.2) sessions. Once acquisition criteria were met, the mean (± SEM) levels of methamphetamine-appropriate responding produced by saline and the 1.0 mg/kg methamphetamine training dose were 3.22% (± 0.90) and 96.9% (± 1.45), respectively. As the dose effects of methamphetamine were consistent throughout the course of this study, the methamphetamine curve presented in the figures reflects the mean of each determination. Figure 1 illustrates the dose effects of methamphetamine, MK-801 and ketamine (left panels), ifenprodil, CNQX, and MPEP (right panels) for percentage of responses on the methamphetamine-appropriate lever and response rate. For methamphetamine, ANOVA revealed a significant main effect of dose (F 3,15 = 9.91, P < 0.001) on the percentage of responses on the methamphetamine-appropriate lever; post-hoc tests indicated that the 0.56 and 1.0 mg/kg doses of methamphetamine produced significantly greater levels of methamphetamine-appropriate responding than saline. In addition, ANOVA also revealed a significant main effect of methamphetamine dose on response rates (F 3,15 = 6.12, P < 0.01); post-hoc tests indicated that 1.0 mg/kg of methamphetamine produced a significant reduction in response rate relative to saline. For MK-801, ketamine, ifenprodil, CNQX, and MPEP, significant dose effects for the percentage of responses on the methamphetamineappropriate lever were not observed; the only dose producing greater than 20% of responses on the methamphetamine lever was 0.3 mg/kg of MK-801 (27.8% methamphetamine-appropriate responding). In contrast, ANOVA revealed significant main effects of MK-801 (F 3,15 = 4.96, P < 0.01), ketamine (F 3,15 = 13.01, P < 0.001), ifenprodil (F 3,15 = 7.59, P < 0.01), CNQX (F 3,15 = 5.61, P < 0.01), and MPEP (F 3,15 = 8.06, P < 0.001) dose on response rates. Significant reductions in response rate were produced by 0.3 mg/kg dose of MK-801, 5.6 and 10 mg/kg of ketamine, ifenprodil, and MPEP, and the 10 mg/kg of CNQX, relative to saline. Figure 2 illustrates the dose effects of methamphetamine (0.1-1.0 mg/kg) in combination with MK-801 (0.03 or 0.1 mg/kg) or saline vehicle for percentage of responses on the methamphetamine-appropriate lever (upper panel) and response rate (lower panel). For percent methamphetamine-appropriate responding, ANOVA revealed a significant main effect of methamphetamine dose (F 3,15 = 27.34, P < 0.001). The main effect of MK-801 pretreatment approached significance (P = 0.07), but the MK-801 pretreatment Â methamphetamine dose interaction did not attain significance. Thus, MK-801 did not alter significantly the potency of methamphetamine. For response rate, ANOVA revealed a significant main effect of methamphetamine dose (F 3,45 = 15.70, P < 0.001); however, no significant main effects or interactions for the MK-801 pretreatment factor on response rate were obtained. Figure 3 illustrates the dose effects of methamphetamine (0.1-1.0 mg/kg) in combination with ketamine (1 or 3 mg/kg) or saline vehicle for percentage of responses on the methamphetamine-appropriate lever (upper panel) and response rate (lower panel). For percent methamphetamine-appropriate responding, ANOVA revealed significant main effects of ketamine pretreatment (F 2,10 = 4.61, P < 0.05) and methamphetamine dose (F 3,15 = 24.16, P < 0.001); however, the ketamine pretreatment and methamphetamine dose interaction failed to attain significance. For response rate, ANOVA revealed a significant main effect of methamphetamine dose (F 3,45 = 13.49, P < 0.001); however, no significant main effects or interactions for the ketamine pretreatment factor on response rate were obtained. Figure 4 illustrates the dose effects of methamphetamine (0.1-1.0 mg/kg) in combination with 5.6 mg/kg of ifenprodil (left panels), CNQX (middle panels), and MPEP (right panels) for percentage of responses on the methamphetamine-appropriate lever (upper panels) and response rate (lower panels). With 5.6 mg/kg of ifenprodil, ANOVA revealed significant main effects of ifenprodil pretreatment (F 1,10 = 10.19, P < 0.01) and methamphetamine dose (F 4,40 = 19.84, P < 0.001) for percent methamphetamine-appropriate responding, although the methamphetamine dose and ifenprodil pretreatment interaction did not attain significance. The 0.3 mg/kg dose of methamphetamine after ifenprodil pretreatment elicited significantly greater levels of methamphetamineappropriate responding than the same dose given after vehicle. Further, ANOVA revealed significant main effects of ifenprodil pretreatment (F 1,10 = 9.39, P < 0.05) and methamphetamine dose (F 3,30 = 17.48, P < 0.001), and a Discriminative stimulus and response rate effects of N-methyl-Daspartate, a-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate, and metabotropic 5 glutamate receptor antagonists. The effects of methamphetamine (0.1-1.0 mg/kg), MK-801 (0.03-0.3 mg/kg), and ketamine (1-10 mg/kg) are illustrated on the left, and the effects of ifenprodil (1-10 mg/kg), 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) (1-10 mg/kg), and 6-methyl-2-(phenylethynyl)pyridine (MPEP) (1-10 mg/kg) are illustrated on the right. Data reflect the mean ( ± standard error of the mean) percentage of responses occurring on the methamphetamine-appropriate lever (upper panels), or the mean ( ± standard error of the mean) percentage of vehicle response rates (lower panels), as a function of dose. Saline alone elicited a mean level of 3.22% methamphetamine-appropriate responding at an average rate of 0.98 responses per second (results not shown). Data points reflect the average effects obtained in rats (n = 6) trained to discriminate 1.0 mg/kg of methamphetamine from saline.
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significant ifenprodil pretreatment and methamphetamine dose interaction (F 3,30 = 3.01, P < 0.05), for response rates. Post-hoc tests indicated that the effects of 0.3 mg/kg of methamphetamine differed significantly after ifenprodil pretreatment compared with vehicle pretreatment. With 5.6 mg/kg of CNQX, ANOVA revealed a significant main effect of methamphetamine dose (F 3,30 = 20.33, P < 0.001), although there were no main effects or interactions for CNQX pretreatment. There was a significant main effect of methamphetamine dose (F 3,30 = 17.14, P < 0.001) on response rate, but CNQX pretreatment had no significant effect on responding. With 5.6 mg/kg of MPEP, ANOVA revealed a significant main effect of methamphetamine dose (F 3,30 = 18.15, P < 0.001) for percent methamphetamine-appropriate responding, although there were no significant main effects or Effects of vehicle (white symbols) or ketamine (1 and 3 mg/kg; gray and black symbols, respectively) on the discriminative stimulus and response rate effects of methamphetamine (0.1-1.0 mg/kg). Data reflect the mean ( ± standard error of the mean) percentage of responses occurring on the methamphetamine-appropriate lever (upper panel), or the mean ( ± standard error of the mean) percentage of vehicle response rates (lower panel), as a function of methamphetamine dose. Data points reflect the average effects obtained in rats (n = 6) trained to discriminate 1.0 mg/kg of methamphetamine from saline.
interactions for MPEP pretreatment. In contrast, ANOVA revealed significant main effects of MPEP pretreatment (F 1,10 = 5.22, P < 0.05) and methamphetamine dose (F 3,30 = 11.74, P < 0.001) on response rate, and a significant MPEP pretreatment and methamphetamine dose interaction (F 1,10 = 3.02, P < 0.05). Post-hoc tests indicated that the effects of 0.3 mg/kg of methamphetamine differed significantly between pretreatment conditions.
Discussion
The purpose of this study was to probe for potential glutamatergic mechanisms in the discriminative stimulus effects of methamphetamine. A variety of receptor subtype-selective ligands, including the NMDA receptor channel blockers, MK-801 and ketamine, the polyamine site NMDA receptor antagonist, ifenprodil, the AMPA receptor antagonist, CNQX, and the mGluR5 antagonist, MPEP, were tested for both production of methamphetamine-like effects and the ability to alter the effects of methamphetamine. Overall, none of the compounds tested elicited methamphetamine-like interoceptive effects when administered alone. In interaction tests, ketamine and ifenprodil each produced leftward shifts in the methamphetamine dose-response curve (and the effect of MK-801 nearly attained significance). Collectively, these results suggest that inhibition of NMDA glutamate receptors may contribute to the methamphetamine cue, whereas the AMPA and mGluR5 subtypes do not appear to play a role.
There have been at least two prior studies of the discriminative effects of MK-801 in methamphetaminetrained rats (Liang and Zheng, 2000; Gatch and Pratt, 2006) . The findings of this study suggesting an effect of MK-801 (P = 0.07) are generally concordant with the results of Gatch and Pratt 2006 who reported that 0.1 mg/kg of MK-801 produced no more than approximately 15% methamphetamine-appropriate responding given alone, yet shifted the methamphetamine dose-response Effects of 5.6 mg/kg of infenprodil (left panels), 5.6 mg/kg of 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) (middle panels), and 5.6 mg/kg of 6-methyl-2-(phenylethynyl)pyridine (MPEP) (right panels) on the discriminative stimulus and response rate effects of methamphetamine (0.1-1.0 mg/kg). Data reflect the mean ( ± standard error of the mean) percentage of responses occurring on the methamphetamine-appropriate lever (upper panels), or the mean ( ± standard error of the mean) percentage of vehicle response rates (lower panels), as a function of methamphetamine dose. Data points reflect the average effects obtained in rats (n = 6) trained to discriminate 1.0 mg/kg of methamphetamine from saline.
curve leftward when administered before methamphetamine. In contrast, Liang and Zheng (2000) reported that 0.1 mg/kg of MK-801 resulted in partial-to-full substitution for methamphetamine when given alone, yet pretreatment with 0.1 mg/kg of MK-801 reduced the level of methamphetamine-appropriate responding elicited by the 1.0 mg/kg methamphetamine training dose from 97 to 43%, indicative of antagonism of the methamphetamine cue. The basis of the discrepant results of Liang and Zheng (2000) relative to Gatch and Pratt (2006) and the current data are unknown, although methodological differences between these studies may have played a role. For example, Liang and Zheng (2000) used subcutaneous administration of methamphetamine versus the intraperitoneal administration used here and by Gatch and Pratt (2006) . In addition, the effects of MK-801 pretreatment were examined in combination with the methamphetamine training dose only in the study by Liang and Zheng (2000) , whereas MK-801 was tested in combination with a range of methamphetamine doses in the Gatch and Pratt (2006) study. Thus, it is possible that the MK-801 enhancement is observed only with methamphetamine doses lower than the training dose. Together with evidence that MK-801 also potentiates d-amphetamine discrimination (Gaiardi et al., 2001) , the preponderance of data support a facilitatory role of NMDA channel blockade for discrimination of amphetamine-type stimulus effects.
The ability of MK-801 to enhance methamphetamine discrimination highlights the potential involvement of the NMDA glutamate receptor. Accordingly, results obtained with the NMDA channel blocker, ketamine, and the polyamine site NMDA antagonist, ifenprodil, support this notion. Each of these drugs produced effects similar to MK-801 in interaction tests, as pretreatment with 3 mg/kg of ketamine or 5.6 mg/kg of ifenprodil resulted in a leftward shift in the methamphetamine dose-response curve. The similar pattern of results obtained with these compounds is likely due to their common discriminative stimulus effects. Both MK-801 and ketamine substitute fully in ketamine-trained or phencyclidine-trained rats (Koek et al., 1990; Benvenga et al., 1991; Narita et al., 2001) , and MK-801 and ketamine cross-substitute in rhesus monkeys (Koek et al., 1988; France et al., 1989 France et al., , 1991 . Similarly, ifenprodil has been shown to elicit at least partial substitution for the discriminative stimulus effects of ketamine and phencyclidine (Koek et al., 1990; De Vry and Jentzsch, 2003) . The similar effects produced by the NMDA antagonists, MK-801, ketamine, and ifenprodil, support the notion that NMDA blockade may be a component of the methamphetamine cue. In contrast to the NMDA receptor, less information is available with regard to the role of AMPA receptors in the abuse-related effects of methamphetamine. In fact, there are no published studies of the discriminative stimulus effects of the AMPA antagonist, CNQX, in methamphetamine-trained subjects. The findings of this study indicate that neither CNQX itself produces a methamphetamine-like discriminative cue, nor does it alter significantly the methamphetamine dose-response curve. These discrepant results (relative to the NMDA receptor antagonists) are consistent with other studies in the literature showing that NBQX, a structurally related AMPA receptor antagonist, does not produce MK-801-like or ketaminelike discriminative stimulus effects (Jackson et al., 1996; Geter-Douglass and Witkin, 1997) .
Although this study is the first to investigate the stimulus properties of the mGluR5 antagonist, MPEP, in animals trained with methamphetamine, several previous studies have examined interactions between MPEP and the discriminative stimulus effects of other stimulant drugs (Lee et al., 2005; Zakharova et al., 2005; Murray and Bevins, 2007) . In a study using squirrel monkeys trained to discriminate cocaine, Lee et al. (2005) reported that MPEP produced a dose-dependent attenuation of cocaine discrimination, whereas MK-801 shifted the cocaine dose-response curve leftward in those animals. In other studies using rats trained to discriminate nicotine, MPEP did not substitute for nicotine, but produced a slight rightward shift in the nicotine dose-response curve in an operant discrimination task (Zakharova et al., 2005) . Using a Pavlovian task where nicotine served as a conditional stimulus for sucrose availability, Murray and Bevins (2007) reported that MPEP attenuated the effects of nicotine, but only at doses that also reduced motor activity.
On the basis of the results of this study, there appears to be some potential for glutamate compounds as treatments for methamphetamine addiction. However, the relation between discriminative stimulus and reinforcing effects has not been studied extensively. In an intriguing study conducted in rhesus monkeys, Martelle and Nader (2009) used a within-subject design to characterize cocaine discrimination and self-administration using a chained schedule in the same animals. Results of that study revealed that, in all monkeys tested, at least one dose of cocaine functioned as a reinforcer without eliciting cocaine-appropriate responding, indicating that these effects are to some extent dissociable. In another study, Childs et al. (2006) examined acquisition rates of cocaine self-administration in rats that were trained previously to discriminate cocaine, and in rats that were also treated with cocaine before pressing for food rewards, but were not subject to discrimination training. These investigators also reported that cocaine-exposed rats tended to acquire self-administration more readily than naive rats, but that this was true regardless of whether they had been trained to discriminate cocaine, or simply treated with cocaine. Thus, the available preclinical literature has yet to provide compelling evidence that alterations in discriminative stimulus effects translate directly to alterations in reinforcing effects, especially for stimulant drugs. One possibility for this is that such a relation may be more straightforward for other drug classes (e.g. opiates) whose activity is mediated primarily by signaling at specific receptors (e.g. m-opioid). As methamphetamine promotes release of all monoamines (Rothman and Baumann, 2003) , it is possible that the downstream activation of multiple receptors contribute to the abuse liability of this drug. Alternatively, targeting specific consequences of methamphetamine abuse in animal models should also yield valuable information. For instance, a recent study demonstrated that the mGluR5 allosteric modulator, 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide, alleviated deficient object recognition memory resulting from extended methamphetamine selfadministration in rats (Reichel et al., 2011) . Given the current unmet need for methamphetamine abuse treatments, the development and use of multiple animal models may be an important avenue toward the eventual realization of that goal.
